monoclon
antibodi
domin
agent
use
inhibit
biolog
target
molecul
diseas
therapeut
concern
immunogen
product
cost
stabil
oligonucleotid
aptam
compar
affin
specif
target
monoclon
antibodi
whilst
minim
immunogen
high
product
low
cost
high
stabil
thu
promis
inhibitor
rival
antibodi
diseas
therapi
review
compar
detail
advantag
disadvantag
antibodi
aptam
therapeut
applic
summar
recent
progress
aptam
select
modif
approach
present
therapeut
oligonucleotid
aptam
preclin
studi
skelet
diseas
discuss
oligonucleotid
aptam
differ
stage
clinic
evalu
variou
diseas
therapi
includ
macular
degener
cancer
inflamm
coagul
highlight
bright
commerci
futur
potenti
challeng
therapeut
oligonucleotid
aptam
monoclon
antibodi
domin
agent
biomed
field
detect
inhibit
target
molecul
biomed
research
sinc
introduc
highli
sensit
antibodybas
diagnost
therapeut
aggress
appli
industri
without
intellectu
properti
restrict
howev
main
issu
monoclon
antibodi
high
immunogen
low
product
high
cost
low
stabil
recent
oligonucleotid
aptam
becom
promis
agent
compet
antibodi
diagnost
also
therapeut
aptam
short
base
singl
strand
oligonucleotid
ssrnassdna
bind
target
conform
complementar
high
affin
specif
term
aptam
deriv
latin
word
aptu
mean
fix
indic
lock
key
relationship
aptam
target
aptam
tailor
select
variou
target
includ
nucleotid
amino
acid
protein
small
molecul
viru
live
cell
protein
major
target
aptam
research
aptam
select
vitro
process
call
systemat
evolut
ligand
exponenti
enrich
selex
first
develop
three
group
independ
compar
monoclon
antibodi
aptam
possess
similar
affin
specif
minim
immunogen
high
product
low
cost
high
stabil
make
advanc
reagent
detect
inhibit
target
molecul
beyond
monoclon
antibodi
aptam
develop
variou
target
diagnost
therapeut
purpos
therapeut
applic
aptam
develop
broad
spectrum
diseas
includ
aid
cancer
diabet
skelet
diseas
aptam
differ
stage
clinic
trial
treatment
macular
degener
cancer
coagul
inflamm
pegaptanib
aptam
vascular
endotheli
growth
factor
vegf
first
therapeut
aptam
approv
fda
treatment
wet
agerel
macular
degener
wet
amd
success
use
market
open
wide
window
follow
develop
therapeut
oligonucleotid
aptam
review
first
explain
advantag
limit
oligonucleotid
aptam
aspect
immunogen
product
cost
stabil
talk
recent
progress
optim
aptam
select
process
downstream
aptam
modif
summar
therapeut
oligonucleotid
aptam
preclin
studi
skelet
diseas
discuss
oligonucleotid
aptam
differ
stage
clinic
evalu
variou
diseas
therapi
includ
macular
degener
cancer
inflamm
coagul
highlight
bright
commerci
futur
potenti
challeng
therapeut
oligonucleotid
aptam
end
discuss
potenti
target
develop
therapeut
oligonucleotid
aptam
base
known
target
approv
monoclon
antibodi
provid
clear
direct
develop
therapeut
oligonucleotid
aptam
aptam
possess
similar
affin
specif
monoclon
antibodi
import
advantag
antibodi
difficult
develop
monoclon
antibodi
immunogen
aptam
recogn
immun
system
foreign
stimul
neg
immun
respons
small
size
around
kda
hand
special
modif
substitut
c
g
omethylribonucleotid
could
avoid
stimul
immun
respons
aptam
high
immunogen
report
till
pegaptanib
first
aptam
approv
fda
treat
wet
amd
show
immunogen
either
preclin
evalu
anim
clinic
trial
patient
product
cost
identif
antibodi
start
mice
requir
screen
seri
cell
rather
labori
expens
aptam
identifi
vitro
select
condit
control
adjust
demand
nonphysiolog
buffer
nonphysiolog
temperatur
could
use
necessari
aptam
easili
accur
synthes
chemic
method
product
larg
quantiti
aptam
less
expens
less
riski
importantli
batch
batch
variat
aptam
product
stabil
antibodi
protein
sensit
temperatur
would
denatur
degrad
easili
wrong
storag
transport
condit
antibodi
limit
shelf
life
requir
continu
cold
chain
transport
avoid
denatur
aptam
indefinit
shelf
life
temperatur
resist
toler
transport
without
special
requir
cool
elimin
need
continu
cold
chain
longterm
storag
transport
function
aptam
could
regener
easili
even
denatur
denatur
could
easili
revers
thu
aptam
display
distinct
advantag
monoclon
antibodi
diagnost
therapeut
applic
also
barrier
aptam
identif
applic
aptam
degrad
nucleas
serum
short
halfliv
clear
rapidli
circul
due
small
size
therefor
downstream
modif
need
use
vivo
aptam
modif
rather
sequenc
depend
high
risk
fail
modif
may
affect
fold
structur
aptam
lead
loss
function
aptam
identifi
selex
high
specif
vitro
may
fail
inhibit
target
vivo
expect
success
rate
effect
aptam
identif
convent
vitro
aptam
select
method
lower
optim
select
strategi
conjug
specif
aptam
effect
therapeut
payload
micrornassirnassmal
molecul
compoundsmonoclon
antibodi
form
nanocomplex
aptam
guid
target
deliveri
desir
therapeut
aim
help
overcom
barrier
combin
use
aptam
antibodi
novel
therapeut
strategi
show
higher
potenc
use
aptam
antibodi
individu
case
antibodyaptam
pincer
aap
develop
increas
bind
affin
inhibit
potenc
antibodi
aptam
target
figur
antithrombin
aptam
antibodi
conjug
bind
differ
epitop
thrombin
design
aap
signific
lower
dissoci
constant
valu
k
pm
antibodi
alon
k
nm
aptam
alon
k
nm
thrombin
breast
cancer
studi
aap
system
combin
human
epiderm
growth
factor
receptor
drug
target
deliveri
system
aptam
load
doxorubicin
conjug
antibodi
form
drug
target
deliveri
system
system
much
higher
cytotox
ic
nm
tumor
drug
ic
nm
aptam
load
dox
ic
nm
therefor
aap
system
would
help
improv
affin
specif
antibodi
aptam
target
new
drug
develop
exist
highli
toxic
drug
target
deliveri
system
especi
therapeut
develop
mani
malign
gener
aptam
use
combin
antibodi
without
chemic
conjug
exampl
antiplateletderiv
growth
factor
pdgf
aptam
combin
antivegf
antibodi
ranibizumab
show
higher
therapeut
potenc
antibodi
alon
wet
amd
treatment
pass
phase
ii
clinic
evalu
wait
phase
iii
clinic
trial
clinic
trial
id
hand
combin
therapeut
antipdgf
antibodi
antivegf
aptam
also
promis
therapeut
effect
circul
due
small
size
therefor
downstream
modif
need
use
vivo
aptam
modif
rather
sequenc
depend
high
risk
fail
modif
may
affect
fold
structur
aptam
lead
loss
function
aptam
identifi
selex
high
specif
vitro
may
fail
inhibit
target
vivo
expect
success
rate
effect
aptam
identif
convent
vitro
aptam
select
method
lower
optim
select
strategi
conjug
specif
aptam
effect
therapeut
payload
micrornassirnassmal
molecul
compoundsmonoclon
antibodi
form
nanocomplex
aptam
guid
target
deliveri
desir
therapeut
aim
help
overcom
barrier
combin
use
aptam
antibodi
novel
therapeut
strategi
show
higher
potenc
use
aptam
antibodi
individu
case
antibodyaptam
pincer
aap
develop
increas
bind
affin
inhibit
potenc
antibodi
aptam
target
figur
antithrombin
aptam
antibodi
conjug
bind
differ
epitop
thrombin
design
aap
signific
lower
dissoci
constant
valu
kd
pm
antibodi
alon
kd
nm
aptam
alon
kd
nm
thrombin
breast
cancer
studi
aap
system
combin
human
epiderm
growth
factor
receptor
drug
target
deliveri
system
aptam
load
doxorubicin
conjug
antibodi
form
drug
target
deliveri
system
system
much
higher
cytotox
nm
tumor
drug
nm
aptam
load
dox
nm
therefor
aap
system
would
help
improv
affin
specif
antibodi
aptam
target
new
drug
develop
exist
highli
toxic
drug
target
deliveri
system
especi
therapeut
develop
mani
malign
gener
aptam
use
combin
antibodi
without
chemic
conjug
exampl
antiplateletderiv
growth
factor
pdgf
aptam
combin
antivegf
antibodi
ranibizumab
show
higher
therapeut
potenc
antibodi
alon
wet
amd
treatment
pass
phase
ii
clinic
evalu
wait
phase
iii
clinic
trial
clinic
trial
id
hand
combin
therapeut
antipdgf
antibodi
antivegf
aptam
also
promis
therapeut
effect
aptamerantibodi
conjug
use
directli
target
drug
target
deliveri
reproduc
permiss
refer
upper
antithrombin
antibodi
antithrombin
aptam
bind
differ
site
thrombin
conjug
antibodi
aptam
aap
fold
higher
affin
thrombin
antibodi
aptam
alon
respect
conjug
aminefunction
aptam
maleimid
activ
sulfosuccinimidyl
nmaleimidomethyl
sulfosmcc
thiofunction
antibodi
conjug
nsuccinimidylsacetylthioacet
sata
aptam
antibodi
mix
incub
coval
conjug
lower
antihuman
epiderm
growth
factor
receptor
aptam
conjug
antibodi
conjug
method
aap
load
doxorubicin
aapdox
fold
aptam
load
dox
chang
aptam
bind
dox
releas
aapdox
aapdox
approxim
threeand
sixfold
higher
cytotox
dox
alon
antibodi
alon
respect
aptamerantibodi
conjug
use
directli
target
drug
target
deliveri
reproduc
permiss
refer
upper
antithrombin
antibodi
antithrombin
aptam
bind
differ
site
thrombin
conjug
antibodi
aptam
aap
fold
higher
affin
thrombin
antibodi
aptam
alon
respect
conjug
aminefunction
aptam
maleimid
activ
sulfosuccinimidyl
nmaleimidomethyl
sulfosmcc
thiofunction
antibodi
conjug
nsuccinimidylsacetylthioacet
sata
aptam
antibodi
mix
incub
coval
conjug
lower
antihuman
epiderm
growth
factor
receptor
aptam
conjug
antibodi
conjug
method
aap
load
doxorubicin
aapdox
fold
aptam
load
dox
chang
aptam
bind
dox
releas
aapdox
aapdox
approxim
threeand
sixfold
higher
cytotox
dox
alon
antibodi
alon
respect
method
use
develop
aptam
process
call
selex
origin
perform
describ
gold
ellington
individu
sever
step
selex
find
develop
specif
aptam
figur
first
step
synthesi
screen
librari
contain
larg
number
randomli
combinatori
ssdna
andor
ssrna
random
ssdnarna
one
conserv
sequenc
end
use
primer
bind
amplif
central
random
region
length
random
sequenc
normal
base
number
sequenc
whole
librari
would
enough
librari
divers
second
step
incub
target
protein
random
librari
proper
condit
partit
step
sequenc
bind
target
protein
separ
bind
third
step
bind
sequenc
elut
amplifi
use
pcr
method
ssdna
rtpcr
ssrna
base
conserv
primer
sequenc
step
singl
cycl
selex
complet
would
obtain
small
number
bind
sequenc
last
step
select
process
repeat
round
incub
partit
amplif
result
identif
small
number
bind
sequenc
high
affin
specif
process
optim
gener
bind
sequenc
transform
bacteria
e
coli
sequenc
well
character
postselex
process
specif
aptam
chemic
modifi
stabil
protect
nucleas
vivo
gener
process
convent
selex
method
use
develop
aptam
process
call
selex
origin
perform
describ
gold
ellington
individu
sever
step
selex
find
develop
specif
aptam
figur
first
step
synthesi
screen
librari
contain
larg
number
randomli
combinatori
ssdna
andor
ssrna
random
ssdnarna
one
conserv
sequenc
end
use
primer
bind
amplif
central
random
region
length
random
sequenc
normal
base
number
sequenc
whole
librari
would
enough
librari
divers
second
step
incub
target
protein
random
librari
proper
condit
partit
step
sequenc
bind
target
protein
separ
bind
third
step
bind
sequenc
elut
amplifi
use
pcr
method
ssdna
rtpcr
ssrna
base
conserv
primer
sequenc
step
singl
cycl
selex
complet
would
obtain
small
number
bind
sequenc
last
step
select
process
repeat
round
incub
partit
amplif
result
identif
small
number
bind
sequenc
high
affin
specif
process
optim
gener
bind
sequenc
transform
bacteria
e
coli
sequenc
well
character
postselex
process
specif
aptam
chemic
modifi
stabil
protect
nucleas
vivo
gener
process
convent
selex
mention
aptam
identifi
convent
selex
process
high
specif
may
fail
stimul
inhibit
target
expect
success
rate
effect
aptam
identif
convent
selex
lower
therefor
optim
variat
base
convent
selex
may
requir
case
sever
modif
use
use
research
wide
tabl
counter
neg
selex
usual
perform
posit
selex
exclud
aptam
bind
neg
target
discrimin
highli
similar
structur
use
convent
selex
combin
counter
selex
strategi
aptam
specif
recogn
osteoblast
enter
hepatocyt
peripher
blood
cell
success
develop
target
deliveri
mention
aptam
identifi
convent
selex
process
high
specif
may
fail
stimul
inhibit
target
expect
success
rate
effect
aptam
identif
convent
selex
lower
therefor
optim
variat
base
convent
selex
may
requir
case
sever
modif
use
use
research
wide
tabl
counter
neg
selex
usual
perform
posit
selex
exclud
aptam
bind
neg
target
discrimin
highli
similar
structur
use
convent
selex
combin
counter
selex
strategi
aptam
specif
recogn
osteoblast
enter
hepatocyt
peripher
blood
cell
success
develop
target
deliveri
therapeut
sirna
counter
selex
strategi
could
effect
decreas
advers
effect
caus
offtarget
phenomenon
vivo
toggl
selex
select
method
multipl
posit
target
use
select
aptam
bind
target
exampl
drug
resist
frequent
found
breast
cancer
patient
treat
monoclon
antibodi
mutat
antibodi
bind
site
one
major
reason
drug
resist
aptam
bind
two
differ
site
could
still
effect
one
bind
site
mutat
data
shown
cell
selex
use
live
cell
select
aptam
target
difficult
identifi
isol
genom
sequenc
use
librari
select
obtain
natur
sequenc
genom
bind
particular
target
call
genom
selex
worthwhil
mention
recent
develop
aptam
particl
display
techniqu
yield
aptam
rather
high
affin
round
selex
figur
method
random
ssdnarna
librari
first
preenrich
sever
round
convent
selex
transform
particl
phase
emuls
pcr
modifi
primer
particl
display
multipl
copi
one
ident
sequenc
surfac
could
call
monoclon
particl
monoclon
particl
incub
fluoresc
label
target
bind
remov
nonspecif
bind
target
fluorescenceactiv
cell
sort
fac
could
employ
separ
monoclon
particl
accord
intens
fluoresc
signal
use
fac
affin
aptam
particl
could
measur
time
selex
rather
highthroughput
high
affin
aptam
clone
sequenc
techniqu
dramat
increas
success
rate
aptam
select
especi
target
fail
develop
aptam
convent
selex
offer
effici
econom
approach
gener
aptam
high
qualiti
help
therapeut
aptam
develop
figur
mechan
aptam
particl
display
system
reproduc
permiss
refer
differ
sequenc
ssdnarna
shown
differ
color
therapeut
purpos
oligonucleotid
aptam
could
degrad
easili
serum
modif
selex
requir
stabil
variou
chemic
modif
significantli
improv
stabil
aptam
figur
guanin
rich
grich
thrombin
aptam
ggttggtgtggttgg
typic
popular
model
use
develop
illustr
novel
character
modif
method
aptam
gquadruplex
structur
form
two
stack
gtetrad
central
loop
tgt
optim
stabil
interest
find
ad
extra
guanin
end
caus
decreas
stabil
ad
extra
guanin
end
caus
increas
stabil
indic
themost
aptam
sequenc
depend
found
gquadruplex
rather
common
structur
aptam
especi
dna
aptam
dna
aptam
variou
target
gquadruplex
structur
high
sequenc
ident
high
divers
anoth
group
tri
invert
polar
site
form
fold
aptam
noncommon
structur
ggttggtgtggttgg
structur
higher
stabil
affin
thrombin
although
lower
inhibit
activ
compar
unmodifi
aptam
termin
internucleotid
linkag
first
tri
sens
deoxyoligonucleotid
cap
end
aptam
invert
thymidin
could
increas
stabil
significantli
also
slow
nucleas
degrad
min
unmodifi
min
modifi
snake
venom
phosphodiesteras
digest
invert
thymidin
modif
commonli
use
approach
block
degrad
nucleas
prolong
aptam
halflif
time
serum
aptam
clinic
trial
modifi
method
tabl
besid
invert
thymidin
modif
conjug
also
design
fight
digest
serum
found
conjug
aptam
bigger
size
protect
nucleas
degrad
also
protect
rapid
clearanc
circul
system
vivo
modif
also
use
figur
mechan
aptam
particl
display
system
reproduc
permiss
refer
differ
sequenc
ssdnarna
shown
differ
color
therapeut
purpos
oligonucleotid
aptam
could
degrad
easili
serum
modif
selex
requir
stabil
variou
chemic
modif
significantli
improv
stabil
aptam
figur
guanin
rich
grich
thrombin
aptam
ggttggtgtggttgg
typic
popular
model
use
develop
illustr
novel
character
modif
method
aptam
gquadruplex
structur
form
two
stack
gtetrad
central
loop
tgt
optim
stabil
interest
find
ad
extra
guanin
end
caus
decreas
stabil
ad
extra
guanin
end
caus
increas
stabil
indic
themost
aptam
sequenc
depend
found
gquadruplex
rather
common
structur
aptam
especi
dna
aptam
dna
aptam
variou
target
gquadruplex
structur
high
sequenc
ident
high
divers
anoth
group
tri
invert
polar
site
form
fold
aptam
noncommon
structur
ggttggtgtggttgg
structur
higher
stabil
affin
thrombin
although
lower
inhibit
activ
compar
unmodifi
aptam
termin
internucleotid
linkag
first
tri
sens
deoxyoligonucleotid
cap
end
aptam
invert
thymidin
could
increas
stabil
significantli
also
slow
nucleas
degrad
min
unmodifi
min
modifi
snake
venom
phosphodiesteras
digest
cap
invert
thymidin
modif
commonli
use
approach
block
exonucleas
degrad
nucleas
prolong
aptam
halflif
time
serum
aptam
clinic
trial
modifi
method
tabl
besid
invert
thymidin
modif
biotinstreptavidin
conjug
also
design
fight
exonucleas
digest
serum
found
biotinstreptavidin
conjug
aptam
bigger
size
protect
nucleas
degrad
also
protect
rapid
clearanc
circul
system
vivo
biotin
modif
also
use
aptam
target
antisar
coronaviru
helicas
aptam
remain
intact
h
fetal
bovin
serum
compar
h
unmodifi
aptam
cholesterol
ad
aptam
form
cholesteryloligonucleotid
cholodn
link
low
densiti
lipoprotein
ldl
form
compact
cholodnldl
complex
complex
high
stabil
highli
resist
nucleas
degrad
serum
longer
halflif
unmodifi
aptam
substitut
phosphodiest
linkag
dna
methylphosphon
phosphorothio
also
commonli
use
aptam
stabil
cholesterol
ad
end
aptam
form
cholesteryloligonucleotid
cholodn
link
low
densiti
lipoprotein
ldl
form
compact
cholodnldl
complex
complex
high
stabil
highli
resist
nucleas
degrad
serum
longer
halflif
unmodifi
aptam
substitut
phosphodiest
linkag
dna
methylphosphon
phosphorothio
also
commonli
use
aptam
stabil
natur
oligonucleotid
dform
lform
oligonucleotid
spiegelm
chiral
invers
natur
dform
identif
lform
aptam
dform
aptam
firstli
select
synthes
lform
protein
target
gener
singl
strand
random
oligonucleotid
librari
selex
lform
aptam
synthes
accord
mirror
imag
correspond
dform
aptam
lform
aptam
much
stabl
dform
high
resist
nucleas
degrad
vivo
hybrid
affect
origin
nucleic
acid
cell
clinic
evalu
aptam
lform
aptam
lock
nucleic
acid
lna
modif
sugar
ring
methylen
linkag
c
gener
stabl
pair
dramat
increas
themost
nucleas
resist
aptam
lnadna
chimera
aptam
transactiv
respons
target
could
retain
intact
structur
without
degrad
h
serum
unlock
nucleic
acid
una
opposit
modif
lna
bond
miss
una
make
aptam
flexibl
differ
lna
stabil
structur
una
uncertain
affect
themost
aptam
found
una
replac
loop
region
antithrombin
aptam
increas
themost
replac
gtetrad
disrupt
structur
format
uncertain
whether
una
modif
effect
protect
aptam
nucleas
degrad
posit
sugar
ring
could
amend
chemic
modif
f
c
aminoethyl
thymidin
deoxyuridin
modif
detail
pleas
read
review
written
wang
et
al
studi
requir
character
discuss
stabil
effect
modif
design
modif
strategi
futur
number
bone
marrow
mesenchym
stem
cell
bmsc
decreas
age
increas
adipocyt
differenti
found
level
much
higher
bmsc
old
young
mice
human
anim
lack
protect
agerel
bone
loss
fat
accumul
bone
marrow
aptam
specif
recogn
bmsc
develop
conjug
form
nanocomplex
target
deliveri
nanocomplex
could
promot
bone
format
reduc
fat
accumul
bone
marrow
high
efficaci
age
mice
indic
potenti
approach
agerel
bone
loss
therapi
furthermor
bmsc
import
bone
marrow
specif
marker
surfac
make
difficult
isol
bone
marrow
directli
aptam
high
bind
affin
porcin
bmsc
develop
selex
use
high
affin
specif
aptam
bmsc
could
fish
cell
solut
bone
marrow
novel
method
bmsc
isol
provid
foundat
aptam
applic
tissu
engin
regen
medicin
skelet
diseas
therapi
anoth
preliminari
studi
specif
aptam
human
jaw
periost
cell
jpc
develop
tissu
engin
oral
maxillofaci
surgeri
aptam
high
affin
human
osteogen
induc
jpc
bmsc
bone
marrow
bind
cell
line
undifferenti
jpc
jpc
induc
sourc
use
purifi
osteogen
progenitor
cell
undifferenti
jpc
stem
cell
sourc
miner
capac
higher
aptam
posit
fraction
promis
techniqu
tissu
engin
aptam
aptamerligand
complex
develop
studi
preclin
research
moment
howev
aptam
evalu
clinic
trial
effort
studi
need
therapeut
field
futur
adult
mesenchym
stem
cell
amsc
stem
cell
moment
aptam
evalu
clinic
trial
treatment
macular
degener
cancer
inflamm
coagul
one
approv
fda
treatment
amd
section
review
research
clinic
evalu
progress
aptam
wet
neovascular
dri
atroph
amd
two
major
caus
vision
loss
elderli
due
retin
damag
affect
around
eight
million
peopl
america
three
aptam
evalu
clinic
trial
wet
dri
amd
therapi
pegaptanib
macugen
pfizer
eyetech
new
york
ny
usa
rna
aptam
specif
bind
inhibit
vegf
amd
aptam
approv
fda
diseas
treatment
market
pegaptanib
select
directli
vegf
vegf
isoform
primarili
respons
patholog
ocular
neovascularizt
vascular
permeabl
vitro
select
character
aptam
inhibit
vegf
high
affin
efficaci
chosen
modifi
fluoro
pyrimidin
omethyl
purin
cap
link
deoxythymidin
avoid
nucleas
degrad
increas
stabil
preclin
anim
studi
kda
polyethylen
glycol
peg
conjug
end
rna
aptam
increas
half
life
aptam
better
bioavail
around
year
preclin
studi
optim
evalu
therapeut
potenc
pegaptanib
show
high
efficaci
inhibit
vegf
differ
model
approv
fda
treatment
amd
dosag
mg
per
eye
everi
week
administ
intravitr
extraordinari
progress
first
aptam
approv
use
human
open
wide
window
therapeut
aptam
diseas
treatment
howev
pegaptanib
fail
compet
antivegf
monoclon
antibodi
ranibizumab
lucenti
genentech
south
san
francisco
california
usa
inhibit
vegf
isoform
antibodi
inhibit
isoform
vegf
neg
affect
pharmaci
invest
therapeut
aptam
year
fortun
found
recent
block
activ
vegf
may
caus
high
risk
hypertens
advers
effect
therefor
aptam
pegaptanib
better
antibodi
ranibizumab
long
term
mainten
therapi
especi
patient
system
comorbid
ophthotech
corp
new
york
ny
usa
base
rna
aptam
specif
complement
compon
treatment
wet
dri
amd
downstream
proinflammatori
protein
complement
system
associ
amd
pathogenesi
inhibit
prevent
key
termin
fragment
format
critic
tissu
patholog
peg
also
conjug
end
invert
thymidin
phase
clinic
trial
use
combin
ranibizumab
treatment
wet
amd
finish
phase
clinic
dri
amd
treatment
recent
complet
data
shown
may
suffici
inhibit
vegf
wet
amd
treatment
prevent
angiogenesi
due
limit
new
vessel
regress
associ
vision
loss
pdgf
play
import
role
pericyt
recruit
matur
new
vessel
may
resist
antivegf
drug
due
role
pdgf
combin
treatment
use
pegaptanib
antipdgf
antibodi
prevent
new
vessel
format
also
promot
vessel
regress
hand
combin
treatment
use
antipdgf
aptam
antivegf
antibodi
also
promis
therapeut
effect
base
rna
aptam
fovista
ophthotech
corp
target
pdgf
develop
modifi
fluoro
pyrimidin
omethyl
purin
preclin
studi
pegconjug
abl
facilit
neovascular
regress
combin
antivegf
agent
clinic
trial
patient
treat
combin
antivegf
antibodi
raninizumab
administ
month
show
signific
neovascular
regress
increas
visual
acuiti
three
month
treatment
without
side
effect
observ
phase
ii
clinic
trial
combin
therapi
patient
treat
combin
therapi
gain
higher
vision
patient
treat
antivegf
antibodi
ranizumab
combin
therapi
wait
phase
iii
clinic
evalu
wet
amd
treatment
moment
clinic
trial
id
promis
result
suggest
combin
therapi
target
two
differ
antigen
time
use
aptameraptam
combin
aptamerantibodi
combin
could
new
therapeut
direct
futur
studi
cancer
treatment
requir
effect
precis
therapi
especi
specif
therapi
discrimin
normal
cell
tumor
cell
avoid
toxic
highli
disorgan
vessel
architectur
insid
tumor
surround
extracellular
matrix
well
stromal
cell
barrier
drug
deliveri
monoclon
antibodi
recogn
target
tumor
cell
high
specif
difficult
penetr
deep
site
tumor
cell
due
larg
size
around
kda
aptam
much
smaller
size
around
kda
abl
cross
barrier
penetr
tumor
cell
therefor
ideal
therapeut
reagent
cancer
gener
aptam
could
diffus
tumor
min
inject
exampl
fluoresc
aptam
extracellular
matrix
protein
tenascinc
abl
diffus
tumor
rapidli
perivascular
fluoresc
signal
detect
tumor
min
intraven
inject
furthermor
anoth
group
compar
tumor
penetr
time
aptam
antibodi
found
detect
tumor
min
h
intraven
inject
respect
immunotherapi
cancer
aptam
recent
novel
research
focu
two
individu
aptam
cancer
therapi
evalu
clinic
trial
antisoma
london
uk
guaninerich
aptam
gquadruplex
structur
identifi
guaninerich
ssrna
librari
antiprolifer
select
gquadruplex
structur
highli
stabl
resist
nucleas
degrad
penetr
tumor
cell
easili
bind
extern
domain
nucleolin
protein
overexpress
surfac
cancer
cell
respons
surviv
growth
prolifer
cell
inhibit
type
cancer
cell
vitro
studi
first
oligonucleotid
aptam
approv
clinic
trial
human
cancer
therapi
preclin
studi
inhibit
efficaci
multipl
cancer
model
includ
nonsmal
cell
lung
renal
cell
breast
cancer
phase
clinic
trial
well
toler
patient
advanc
cancer
side
effect
show
promis
therapeut
efficaci
especi
patient
renal
cell
carcinoma
six
month
therapi
phase
ii
clinic
trial
show
therapeut
efficaci
acut
myeloid
leukemia
patient
without
toxic
advers
effect
howev
follow
phase
ii
evalu
renal
cell
carcinoma
clinic
trial
id
found
therapeut
effect
patient
show
minim
activ
unselect
patient
metastat
renal
cell
carcinoma
indic
research
requir
optim
therapeut
potenc
futur
olaptes
pegol
noxxon
berlin
germani
lrna
aptam
develop
use
autolog
hematopoiet
stem
cell
transplant
target
stroma
cellderiv
chemokin
cxc
motif
ligand
play
import
role
stem
cell
migrat
toward
bone
marrow
control
tumor
growth
metastasi
vasculogenesi
bind
block
receptor
bind
prevent
tissu
gradient
decreas
possibl
tumor
metastasi
drug
resist
caus
cancer
cell
home
lform
aptam
recogn
nucleas
requir
chemic
modif
vivo
studi
show
efficaci
nonhodgkin
lymphoma
myeloma
preclin
studi
phase
clinic
trial
safeti
toler
evalu
confirm
well
toler
without
seriou
advers
effect
h
long
halflif
patient
treatment
suscept
chemotherapi
due
particular
blockag
stromal
cellderiv
make
promis
success
drug
cancer
therapi
two
phase
ii
clinic
trial
progress
one
treatment
chromin
lymphocyt
leukemia
clinic
trial
id
one
evalu
compar
therapeut
efficaci
alon
combin
therapi
chemotherapi
patient
multipl
myeloma
clinic
trial
id
aptam
coagul
therapi
develop
independ
differ
research
group
till
four
aptam
evalu
differ
stage
clinic
trial
regado
bioscienc
bask
ridg
nj
usa
aptam
system
consist
rna
aptam
pegnivacogin
antidot
sequenc
complementari
antagonist
factor
ixa
prevent
downstream
convers
factor
x
avoid
clot
antidot
specif
revers
inhibit
function
control
sheath
remov
time
percutan
coronari
intervent
phase
clinic
trial
shown
well
toler
patient
signific
advers
effect
major
bleed
found
importantli
therapeut
effect
control
dosag
less
toxic
heparinprotamin
also
anticoagulationantidot
pair
current
avail
phase
ii
clinic
trial
use
percutan
coronari
intervent
patient
coronari
arteri
complet
clinic
trial
id
howev
later
random
clinic
trial
termin
finish
patient
treat
show
sever
allerg
reaction
major
bleed
signific
efficaci
percutan
coronari
intervent
therefor
studi
requir
evalu
safeti
efficaci
system
archemix
corp
cambridg
usa
pegyl
dna
aptam
bind
domain
von
willebrand
factor
vwf
key
factor
coagul
cascad
relat
platelet
recruit
block
interact
domain
platelet
receptor
glycoprotein
therefor
potenti
therapeut
target
treatment
vwfrelat
platelet
disord
von
willebrand
diseas
well
acut
coronari
syndrom
phase
ii
pilot
studi
show
inhibit
platelet
deplet
induc
vwf
agonist
desmopressin
patient
phase
ii
clinic
trial
vwf
treatment
still
ongo
aptam
arca
biopharma
london
uk
unmodifi
dna
aptam
shortterm
anticoagul
distinct
longterm
anticoagul
aptam
preclin
studi
show
efficaci
prolong
clot
time
anticoagul
effect
would
stop
rapidli
due
nucleas
degrad
phase
ii
clinic
trial
evalu
therapeut
effect
coronari
arteri
bypass
graft
surgeri
progress
clinic
trial
id
three
anticoagul
aptam
target
protein
intrins
coagul
pathway
baxter
deerfield
il
usa
target
neg
regul
factor
viia
extrins
tissu
factor
pathway
preclin
hemophilia
patholog
mimick
monkey
model
abl
recov
clot
caus
antifactor
viii
antibodi
phase
clinic
trial
start
clinic
trial
id
evalu
result
publish
yet
two
antiinflamm
aptam
clinic
trial
lform
aptam
noxxon
hepcidin
overexpress
patient
chronic
inflamm
induc
cancer
dialysi
may
lead
anemia
due
hepcidininduc
ferroportin
degrad
lexaptepid
pegol
noxxon
target
hepcidin
peptid
hormon
regul
iron
homeostasi
role
inhibit
interact
hepcidin
ferroportin
reduc
anemia
symptom
patient
preclin
studi
cynomolgu
monkey
could
prevent
induc
iron
concentr
decreas
serum
treat
phase
iia
clinic
trial
anemia
therapeut
evalu
patient
cancer
complet
clinic
trial
treatment
erythropoiesi
agentinduc
anemia
patient
dialysi
still
progress
clinic
trial
id
anoth
lform
antiinflamm
aptam
noxxon
target
chemokin
ligand
also
call
monocyt
chemoattract
protein
mediat
inflamm
recruit
leukocyt
intravascular
extravascular
environ
upon
bind
inhibit
chemokin
ligand
inflamm
reduc
recruit
leukocyt
quit
effect
antiinflamm
treatment
lupu
nephriti
mous
model
also
use
prevent
diabet
glomerulosclerosi
mice
phase
ii
clinic
trial
treatment
diabet
progress
clinic
trial
id
oligonucleotid
aptam
popular
recent
year
especi
first
aptam
pegaptanib
approv
wet
amd
therapi
fda
aptam
develop
selex
broad
spectrum
diagnost
therapeut
applic
find
report
aptam
research
pubm
number
current
gener
increas
two
five
everi
day
aptam
clinic
trial
advantag
especi
safeti
issu
signific
improv
efficaci
therapeut
applic
addit
aptam
nearli
aptam
wait
approv
evalu
clinic
trial
promis
advantag
compar
monoclon
antibodi
oligonucleotid
aptam
may
becom
predomin
agent
therapeut
applic
monoclon
antibodi
technolog
commonli
develop
use
therapeut
applic
target
antibodi
well
character
tabl
therefor
futur
base
promis
therapeut
effect
inhibit
particular
target
monoclon
antibodi
oligonucleotid
aptam
identifi
target
develop
second
gener
therapi
would
save
consider
research
effort
allow
rapid
progress
develop
econom
effici
therapeut
approach
variou
diseas
oligonucleotid
aptam
author
declar
conflict
interest
follow
abbrevi
use
manuscript
nsuccinimidylsacetylthioacet
chemokin
cxc
motif
ligand
